These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
64. Dysregulation of lysosomal morphology by pathogenic LRRK2 is corrected by TPC2 inhibition. Hockey LN; Kilpatrick BS; Eden ER; Lin-Moshier Y; Brailoiu GC; Brailoiu E; Futter CE; Schapira AH; Marchant JS; Patel S J Cell Sci; 2015 Jan; 128(2):232-8. PubMed ID: 25416817 [TBL] [Abstract][Full Text] [Related]
65. Ca(2+) signals, NAADP and two-pore channels: role in cellular differentiation. Parrington J; Tunn R Acta Physiol (Oxf); 2014 Jun; 211(2):285-96. PubMed ID: 24702694 [TBL] [Abstract][Full Text] [Related]
66. The endo-lysosomal system as an NAADP-sensitive acidic Ca(2+) store: role for the two-pore channels. Patel S; Ramakrishnan L; Rahman T; Hamdoun A; Marchant JS; Taylor CW; Brailoiu E Cell Calcium; 2011 Aug; 50(2):157-67. PubMed ID: 21529939 [TBL] [Abstract][Full Text] [Related]
67. Function and dysfunction of two-pore channels. Patel S Sci Signal; 2015 Jul; 8(384):re7. PubMed ID: 26152696 [TBL] [Abstract][Full Text] [Related]
68. Inhibition of NAADP signalling on reperfusion protects the heart by preventing lethal calcium oscillations via two-pore channel 1 and opening of the mitochondrial permeability transition pore. Davidson SM; Foote K; Kunuthur S; Gosain R; Tan N; Tyser R; Zhao YJ; Graeff R; Ganesan A; Duchen MR; Patel S; Yellon DM Cardiovasc Res; 2015 Dec; 108(3):357-66. PubMed ID: 26395965 [TBL] [Abstract][Full Text] [Related]
69. Reconstitution of lysosomal NAADP-TRP-ML1 signaling pathway and its function in TRP-ML1(-/-) cells. Zhang F; Xu M; Han WQ; Li PL Am J Physiol Cell Physiol; 2011 Aug; 301(2):C421-30. PubMed ID: 21613607 [TBL] [Abstract][Full Text] [Related]
70. Essential requirement for two-pore channel 1 in NAADP-mediated calcium signaling. Brailoiu E; Churamani D; Cai X; Schrlau MG; Brailoiu GC; Gao X; Hooper R; Boulware MJ; Dun NJ; Marchant JS; Patel S J Cell Biol; 2009 Jul; 186(2):201-9. PubMed ID: 19620632 [TBL] [Abstract][Full Text] [Related]
71. Development of a ligand for in vivo imaging of mutant huntingtin in Huntington's disease. Bertoglio D; Bard J; Hessmann M; Liu L; Gärtner A; De Lombaerde S; Huscher B; Zajicek F; Miranda A; Peters F; Herrmann F; Schaertl S; Vasilkovska T; Brown CJ; Johnson PD; Prime ME; Mills MR; Van der Linden A; Mrzljak L; Khetarpal V; Wang Y; Marchionini DM; Skinbjerg M; Verhaeghe J; Dominguez C; Staelens S; Munoz-Sanjuan I Sci Transl Med; 2022 Feb; 14(630):eabm3682. PubMed ID: 35108063 [TBL] [Abstract][Full Text] [Related]
72. Reconstitution and characterization of a nicotinic acid adenine dinucleotide phosphate (NAADP)-sensitive Ca2+ release channel from liver lysosomes of rats. Zhang F; Li PL J Biol Chem; 2007 Aug; 282(35):25259-69. PubMed ID: 17613490 [TBL] [Abstract][Full Text] [Related]
73. Gossypol, a novel modulator of VCP, induces autophagic degradation of mutant huntingtin by promoting the formation of VCP/p97-LC3-mHTT complex. Li XJ; Zhang YY; Fu YH; Zhang H; Li HX; Li QF; Li HL; Tan RK; Jiang CX; Jiang W; Li ZX; Luo C; Lu BX; Dang YJ Acta Pharmacol Sin; 2021 Oct; 42(10):1556-1566. PubMed ID: 33495516 [TBL] [Abstract][Full Text] [Related]
74. Endolysosomal TPCs regulate social behavior by controlling oxytocin secretion. Martucci LL; Launay JM; Kawakami N; Sicard C; Desvignes N; Dakouane-Giudicelli M; Spix B; Têtu M; Gilmaire FO; Paulcan S; Callebert J; Vaillend C; Bracher F; Grimm C; Fossier P; de la Porte S; Sakamoto H; Morris J; Galione A; Granon S; Cancela JM Proc Natl Acad Sci U S A; 2023 Feb; 120(7):e2213682120. PubMed ID: 36745816 [TBL] [Abstract][Full Text] [Related]
78. Site-specific ubiquitination of pathogenic huntingtin attenuates its deleterious effects. Hakim-Eshed V; Boulos A; Cohen-Rosenzweig C; Yu-Taeger L; Ziv T; Kwon YT; Riess O; Phuc Nguyen HH; Ziv NE; Ciechanover A Proc Natl Acad Sci U S A; 2020 Aug; 117(31):18661-18669. PubMed ID: 32675242 [TBL] [Abstract][Full Text] [Related]
79. Mutant Huntingtin Impairs Pancreatic β-cells by Recruiting IRS-2 and Disturbing the PI3K/AKT/FoxO1 Signaling Pathway in Huntington's Disease. Li L; Sun Y; Zhang Y; Wang W; Ye C J Mol Neurosci; 2021 Dec; 71(12):2646-2658. PubMed ID: 34331233 [TBL] [Abstract][Full Text] [Related]
80. MicroRNA-27a reduces mutant hutingtin aggregation in an in vitro model of Huntington's disease. Ban JJ; Chung JY; Lee M; Im W; Kim M Biochem Biophys Res Commun; 2017 Jun; 488(2):316-321. PubMed ID: 28495533 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]